Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy.

导出 OA

翻译打印收藏纠错

作者： Philippe,Bégin ^[1] ; John Andrew,Bird ^[2] ; Jonathan M,Spergel ^[3] ; Dianne E,Campbell ^[4] ; Todd D,Green ^[5] ; Katharine J,Bee ^[4] ; Romain,Lambert ^[6] ; Hugh A,Sampson ^[4] ; David M,Fleischer ^[4]

作者单位： CHU Sainte-Justine, Montreal, QC, Canada. ^[1] University of Texas Southwestern Medical Center, Dallas, TX, USA. ^[2] Children's Hospital of Philadelphia, Philadelphia, PA, USA. ^[3] DBV Technologies, Montrouge, France. ^[4] The Children's Hospital at Westmead, Sydney, NSW, Australia. ^[5] UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA. ^[6] Icahn School of Medicine at Mount Sinai, New York, NY, USA. ^[7] Children's Hospital Colorado, University of Colorado, Aurora, CO, USA. ^[8]

主题词投药, 口服(Administration, Oral);变应原(Allergens);脱敏法, 免疫(Desensitization, Immunologic);人类(Humans);免疫疗法(Immunotherapy);花生过敏(Peanut Hypersensitivity)

DOI 10.1111/all.15083

PMID 34492123

发布时间 2022-10-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交